Edwards Lifesciences

The latest report details the management of severe mitral regurgitation and torrential tricuspid regurgitation in a 71-year-old patient with a complex cardiovascular history. Learn how Dr. Stefan Toggweiler managed this patient with multiple valvular disease in this EBAC-accredited case study with expert commentary from Prof. Amin Polzin: https://lnkd.in/dEuvMXmJ * *This link leads to a third-party website not controlled by Edwards Lifesciences. Edwards Lifesciences does not have editorial control for the content of the presentations. Expert opinions, advice and all other information expressed represent contributor’s views and not necessarily those of Edwards Lifesciences. EBAC = European Board for Accreditation of Continuing Education for Health Professionals.

Severe tricuspid regurgitation now has multiple approved interventional therapies. See how Dr. Marianna Adamo and Dr. Elisa Pezzola of the University of Brescia choose the optimal treatment for this patient in a newly published EBAC-accredited case study! Learn more with expert commentary from Dr. Matti Adam: https://lnkd.in/djy5jGgp * *This link leads to a third-party website not controlled by Edwards Lifesciences. Edwards Lifesciences does not have editorial control for the content of the presentations. Expert opinions, advice and all other information expressed represent contributor’s views and not necessarily those of Edwards Lifesciences. EBAC = European Board for Accreditation of Continuing Education for Health Professionals.

With every innovation, we moved TEER forward. Innovation is not a single breakthrough. It is a relentless commitment to pushing the boundaries of what is possible. Because advancing transcatheter therapies means continually challenging the status quo to help physicians deliver better outcomes for their patients. Learn more about the PASCAL Precision™ system.

Cardiologist Dr. Adnan Nadir explores the use of transcatheter tricuspid valve to treat severe tricuspid regurgitation in the context of carcinoid heart disease in this complex case involving a 74-year-old woman. Learn more through this EBAC-accredited case study with expert commentary from Dr. Angel Sanchez Recalde: https://lnkd.in/dXXj7z7J * *This link leads to a third-party website not controlled by Edwards Lifesciences. Edwards Lifesciences does not have editorial control for the content of the presentations. Expert opinions, advice and all other information expressed represent contributor’s views and not necessarily those of Edwards Lifesciences. EBAC = European Board for Accreditation of Continuing Education for Health Professionals.

Achieving residual TR ≤ 1+ was associated with better two-year survival as compared to residual TR 2+ in patients undergoing T-TEER.¹ Discover more here*: https://lnkd.in/d497aRiQ 1.Stolz L. et al., JACC Cardiovasc Interv. 2026 May 25;19(10):1319-1321. #EdwardsLifesciences * This link leads to a third-party website not controlled by Edwards Lifesciences. Edwards Lifesciences is not responsible for the content, links, or updates of the linked site. Expert opinions, advice and all other information expressed represent contributors’ views and not necessarily those of Edwards Lifesciences.

Just Published in NEJM: TRIC-I-HF reported hard endpoint benefits for transcatheter tricuspid repair plus medical therapy versus medical therapy alone in severe TR patients* Multicentre investigator-initiated RCT achieved its primary endpoints; Transcatheter tricuspid repair plus medical therapy: ✅ Demonstrated superiority to medical therapy alone with respect to the hierarchical composite of ACM, HFH, and QoL improvement at 1 year ✅ Reduced risk of the composite of ACM or HFH by 60% compared with medical therapy alone through 3 years ✅ Represented commercially available repair products, with approximately 2 of 3 patients treated with the PASCAL TM system * In patients with symptomatic, severe tricuspid regurgitation who were at increased risk for future heart-failure events Hausleiter J., Stocker TJ. et al., Tricuspid-Valve Intervention in Heart Failure. N Engl J Med. 2026; doi:10.1056/NEJMoa2606934. RCT: randomized controlled trial; ACM: all-cause mortality; HFH: heart failure hospitalization; QoL: quality of life Medical device for professional use. See instructions for use. © 2026 Edwards Lifesciences Corporation. All rights reserved. PP--12626 v1.0